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The interferon-inducible restriction factor tetherin (also known as CD317, BST-2 or HM1.24)
has emerged as a key component of the antiviral immune response. Initially, tetherin
was shown to restrict replication of various enveloped viruses by inhibiting the release
of budding virions from infected cells. More recently, it has become clear that tetherin also
acts as a pattern recognition receptor inducing NF-κB-dependent proinﬂammatory gene
expression in virus infected cells. Whereas the ability to restrict virion release is highly
conserved among mammalian tetherin orthologs and thus probably an ancient function
of this protein, innate sensing seems to be an evolutionarily recent activity. The potent
and broad antiviral activity of tetherin is reﬂected by the fact that many viruses evolved
means to counteract this restriction factor. A continuous arms race with viruses has
apparently driven the evolution of different isoforms of tetherin with different functional
properties. Interestingly, tetherin has also been implicated in cellular processes that are
unrelated to immunity, such as the organization of the apical actin network and membrane
microdomains or stabilization of the Golgi apparatus. In this review, I summarize our current
knowledge of the different functions of tetherin and describe the molecular strategies that
viruses have evolved to antagonize or evade this multifunctional host restriction factor.
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INTRODUCTION
In the late 1960s, researchers estimated that the human genome
may contain up to two million protein-coding genes (Kauffman,
1969). Today, we know that the actual number is much lower. In
2012, an in vitro gene expression analysis yielded a number of
20,687 protein-coding genes (Pennisi, 2012). Interestingly, several
hundred of them are interferon-stimulated genes (ISGs) that are
upregulated during viral infections (de Veer et al., 2001; Lanford
et al., 2006; Fernandez-Suarez et al., 2013). Although an antiviral
effector function has been described for some of these factors, the
role of most ISGs during viral infections remains obscure. Three
extensively studied proteins induced by type I interferons (IFN)
are the restriction factors APOBEC3G (apolipoprotein B mRNA-
editing enzyme, catalytic polypeptide-like 3G),TRIM5α (tripartite
motif 5-alpha), and tetherin (BST-2, CD317, or HM1.24). These
host proteins are key players of the innate immune response and
part of the ﬁrst line of defense against lentiviruses. Like other IFN-
inducible proteins, they target speciﬁc steps of the viral life cycle:
APOBEC3G is a cytidine deaminase that inhibits reverse tran-
scription and introduces G-to-A substitutions in the viral genome
(Sheehy et al., 2002), TRIM5α binds incoming viral capsids and
interferes with the uncoating process (Stremlau et al., 2004), and
tetherin inhibits the release of budding virions from infected cells
(Neil et al., 2008; Van Damme et al., 2008).
Surprisingly, the number of human genes is not signiﬁ-
cantly larger than that of many less complex organisms such
as Caenorhabditis elegans or Drosophila melanogaster. Yet, the
number of proteins can of course not be directly inferred from
the number of genes. Alternative pre-mRNA splicing, DNA
rearrangement, post-translational modiﬁcations, RNA editing,
and the use of alternative start codons or reading frames are
means to increase the coding potential of genes. Another pos-
sibility of coping with a limited number of genes is the evolution
of multifunctional proteins, a phenomenon called “gene sharing”
or “moonlighting” (Jeffery, 2003). ISGs may be especially prone to
moonlighting since viruses exert a substantial selection pressure
on the genomes of their host species. Antiviral proteins frequently
have to acquire novel functions to cope with rapidly evolving or
newly emerging viruses. Thus, viral infections may drive the evo-
lution of antiviral activities in proteins that initially only exerted
functions unrelated to immunity. Another common feature of
many host restriction factors is their counteraction by viral antag-
onists. Whereas HIV-1 is resistant against human TRIM5α due to
mutations in its capsid protein (Stremlau et al., 2004),APOBEC3G
and tetherin are directly targeted by the accessory proteins Vif and
Vpu, respectively (Sheehy et al., 2002; Neil et al., 2008;VanDamme
et al., 2008). Notably, the combinationof an antiviral functionwith
activities beyond immunity within one protein may be a means
to impede counteraction by viruses. Antiviral moonlighting pro-
teins that also exert essential cellular functions cannot simply be
degraded as this might be detrimental for the host cell and thus
terminate viral replication.
The host restriction factor tetherin is such a moonlighting pro-
tein fulﬁlling all characteristics of known restriction factors: it is
induced by IFNs, inhibits a speciﬁc step of the viral replication
cycle, shows signatures of positive selection and is counteracted by
viral proteins. In this review, I will summarize our current knowl-
edge of the different activities of tetherin and discuss the strategies
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evolved by different viruses to antagonize or evade this restriction
factor.
STRUCTURE, TOPOLOGY, AND POST-TRANSLATIONAL
MODIFICATIONS
The structural topology of tetherin is almost unique among mam-
malian proteins. Tetherin is a type II transmembrane protein
consisting of a short N-terminal domain followed by an alpha-
helical transmembrane domain, a labile coiled-coil ectodomain
and a C-terminal glycosyl-phosphatidylinositol (GPI) anchor
(Figures 1A and 2A; Kupzig et al., 2003). This unusual topol-
ogy with two membrane anchors is only shared with a special
form of the prion protein (Hegde et al., 1998, 1999; Stewart et al.,
2001), ponticulin from the slime mold Dictyostelium discoideum
(Hitt et al., 1994a,b), Sm23 from Schistosoma mansoni (Köster and
Strand, 1994), and NcSRS2 from Neospora caninum (Nishikawa
et al., 2002).
The N-terminal intracellular domain of tetherin contains
an evolutionarily conserved tyrosine motif (YxY; Figure 1A),
which mediates clathrin-dependent internalization by recruit-
ment of AP2 (Figure 2A; Ohtomo et al., 1999; Blasius et al.,
2006; Rollason et al., 2007; Masuyama et al., 2009). Mature teth-
erin recycles between the plasma membrane, endosomes and the
trans-Golgi-network (TGN) with a mean surface half-life of a few
FIGURE 1 |Tetherin sequences. (A) Alignment of tetherin orthologs from
different mammalian species. Dots indicate identity and gaps (dashes) were
introduced to improve the alignment. Aotus gr. designates the Gray-handed
night monkey Aotus griseimembra, sheep A and B the two tetherin proteins
encoded by sheeps. A dual tyrosine motif that has been shown to be
important for NF-κB activation as well as RICH2 and adapter protein binding is
highlighted in blue, conserved cystein residues that form disulﬁde bridges are
shown in pink and glycosylation sites in gray. Threonine at position 164 of
Aotus tetherin is responsible for the lack of virion retention in this species and
is highlighted in red. A unique stretch of EQ repeats in the hamster ortholog
that may determine Golgi localization is marked in green. Deletions and
truncations in the N-terminal cytoplasmic domain including the
human-speciﬁc ﬁve amino acid deletion are shown in yellow. Two alternative
start codons are indicated by arrows and ω marks the omega site of
GPI-anchor addition. (B) Partial sequence of the human tetherin promoter.
Transcription and translation start sites are indicated by pink and red arrows,
respectively. ATATA box-like sequence is highlighted in orange and STAT3 and
IRF1/ISGF3 binding sites are marked in green and blue, respectively.
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FIGURE 2 |Tetherin functions. (A)Topology of a tetherin dimer: the
N-terminal cytoplasmic domain is followed by an alpha-helical transmembrane
domain, a glycosylated coiled-coil extracellular domain and the GPI-anchor
that is located in lipid rafts (yellow). Adapter proteins bind to a dual tyrosine
motif in the N-terminal domain to induce clathrin-mediated endocytosis. (B) A
tetherin dimer restricting the release of a budding virion is shown.Whereas
the GPI-anchor is incorporated into the viral membrane, the N-terminal
transmembrane domain remains attached to the host cell. TRAFs are
recruited to the N-terminus upon virion binding. Subsequent recruitment of
TABs and activation of TAK1 induces an NF-κB-dependent antiviral immune
response. (C)Tetherin interacts with ILT7 on pDCs. ILT7 forms a complex
with FcεRIγ, which contains a cytoplasmic ITAM. (D)Tetherin forms a picket
fence around lipid rafts and links them to the underlying actin cytoskeleton via
RICH2/EBP50/Ezrin. (E) Hamster tetherin is required for maintenance of the
Golgi apparatus. It may connect and stabilize opposite membranes in the
Golgi cisternae or sense their curvature and distance.
hours (Masuyama et al., 2009; Skasko et al., 2011; Sauter et al.,
2013). Notably, methionine at position 13 of human tetherin has
been shown to serve as alternative start codon, resulting in the
expression of a shorter isoform (Figure 1A; Blasius et al., 2006;
Cocka and Bates, 2012). Although both isoforms are expressed at
comparable levels, the short isoform may preferentially localize to
the plasma membrane due the lack of the YxY endocytosis motif
(Cocka and Bates, 2012).
Mature tetherin is characterized by complex N-linked glyco-
sylation at two conserved asparagine residues in its extracellular
domain (Figure 1A; Ohtomo et al., 1999; Kupzig et al., 2003). Gly-
cosylation occurs in the endoplasmic reticulum (ER) and Golgi
apparatus and is required for entry of tetherin into the secretory
pathway (Kupzig et al., 2003). Nevertheless, tetherin has never
been shown to be secreted. Interestingly, glycosylated tetherin
binds to various lectins with different selectivities (Ohtomo et al.,
1999). However, a functional role of lectin binding by tetherin in
vivo has not been demonstrated yet. In addition to the conserved
asparagine residues, the ectodomain of human tetherin contains
three cysteine residues that mediate disulﬁde-linked homodimer
formation of the mature protein (Figure 1A; Kupzig et al., 2003).
Recently, it has been suggested that interaction of the transmem-
brane domains may also be involved in homodimerization of
tetherin (Cole et al., 2012). Tetherin homodimers are characterized
by a parallel dimeric coiled-coil over the C-terminal two-thirds of
the ectodomain. The N-terminal third may form an antiparallel
four-helix bundle with another dimer, creating a tetherin tetramer
(Schubert et al., 2010; Yang et al., 2010a).
During maturation, the C-terminus of tetherin is cleaved off in
the ER to enable the addition of a GPI-anchor to serine at position
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161 (Figure 1A). Tetherin is trapped in the ER in cells that have
defects in the GPI-biosynthetic pathway (Perez-Caballero et al.,
2009). The GPI-anchor serves as subcellular localization signal
and targets tetherin to cholesterol-rich microdomains (lipid rafts;
Kupzig et al., 2003). In contrast, the N-terminal transmembrane
domain is most likely located outside lipid rafts with the cytosolic
domain being a membrane microdomain exclusion motif (Bill-
cliff et al., 2013). Thus, it has been suggested that parallel tetherin
dimers form a picket fence like structure at the boundary of lipid
rafts (Figure 2D; Kupzig et al., 2003).
EXPRESSION AND INDUCTION
The tetherin core promoter has a size of about 2000 base pairs.
Transcription starts 51 nucleotides upstream of the start codon
and a TATA box-like sequence is located 81 nucleotides upstream
of the start codon (Figure 1B; Ohtomo et al., 1999). The pro-
moter contains consensus binding sites for the transcription
factors STAT3, IRF1, and ISGF3 (Figure 1B), suggesting that
tetherin is an IFN-inducible gene (Ohtomo et al., 1999; Kawai
et al., 2006; Ge et al., 2006). Indeed, it has been shown that IFN-
α, -β, -γ, -τ, -λ3, and -ω induce the expression of tetherin
in various cell types from different species (Blasius et al., 2006;
Arnaud et al., 2010; Dietrich et al., 2011; Cobos Jiménez et al.,
2012; Liu et al., 2012; Amet et al., 2014). Like other ISGs, teth-
erin expression is upregulated upon viral infection and protein
levels correlate with viral loads both, in HIV-infected humans
and simian immunodeﬁciency viruses (SIV)-infected macaques
(Homann et al., 2011; Mous et al., 2012; Rahmberg et al., 2013).
Retroviral infection is sensed by various pattern recognition recep-
tors (PRR) such as TLRs, RIG-I, or IFI16 thereby inducing the
release of type I IFNs and subsequent upregulation of teth-
erin (Blasius et al., 2006; Zhou et al., 2010; Jakobsen et al., 2013;
Tavano et al., 2013; Wang et al., 2013). Interestingly, several IFN-
independent stimulants of tetherin have also been reported. Bego
et al. (2012) for example showed that TLR3 and TLR8 stimula-
tion are able to induce the expression of tetherin independently
of IFNs. Similarly, IL-27 has been identiﬁed as a potent inducer
of tetherin in the absence of IFN (Guzzo et al., 2012). In con-
trast, IL-4, IL-6, IL-10, IL-12, TNFα, and CD40L have no or only
marginal effects on tetherin expression levels (Blasius et al., 2006;
Tavano et al., 2013) and its expression is downmodulated by TGFβ
(Sayeed et al., 2013).
Although tetherin expression levels are markedly upregulated
upon IFN stimulation, many cell types constitutively express teth-
erin in the absence of viral infections. Tetherin was originally
identiﬁed as a marker for bone marrow stromal cells and various
tumor cells (Goto et al., 1994; Ishikawa et al., 1995; Ohtomo et al.,
1999;Walter-Yohrling et al., 2003; Grützmann et al., 2005; Capurso
et al., 2006; Cai et al., 2009). More recently, it has become clear
that tetherin is more widely expressed and can be detected to high
levels in hepatocytes, pneumocytes, activated T cells, monocytes,
pDCs, ducts of major salivary glands, pancreas and kidney cells,
vascular endothelium, and many other cell types (Vidal-Laliena
et al., 2005; Blasius et al., 2006; Kawai et al., 2006; Erikson et al.,
2011). This constitutive expression in many organs and tissues
suggests that tetherin is a key player of the early innate immune
response. Alternatively, constitutive expression may indicate that
tetherin performs cellular functions beyond immunity that require
expression also in the absence of IFN and viral infections.
FUNCTIONS
INHIBITION OF VIRUS RELEASE
Although tetherin had already been described as an interferon-
inducible gene in the 1990s, it took until 2008 to discover the
potent antiviral activity of this cellular protein. In this year, two
groups reported the ability of tetherin to inhibit the release of bud-
ding HIV virions from infected cells (Neil et al., 2008; Van Damme
et al., 2008). Electron microscopic analyses revealed that tetherin
appears to tether virions to each other as well as to the plasma
membrane (Figure 2B; Neil et al., 2007, 2008). This antiviral activ-
ity depends on the unusual topology of tetherin. Budding virions
incorporate one of the two membrane anchors of the restriction
factor, whereas the other one remains attached to the plasma
membrane of the host cell (Neil et al., 2008; Van Damme et al.,
2008; Perez-Caballero et al., 2009). Using sophisticated modiﬁed
tetherin variants, Venkatesh and Bieniasz (2013) could show that
tetherin dimers adopt a parallel conﬁguration with a three- to ﬁve-
fold preference for the insertion of the GPI-anchor rather than the
transmembrane domain into virions. This is in agreementwith the
observation that HIV progeny virions bud from cholesterol-rich
microdomains (Nguyen and Hildreth, 2000; Bhattacharya et al.,
2006). Microscopic analyses showed that tetherin accumulates
at HIV budding sites with around four to seven molecules per
assembly cluster (Habermann et al., 2010; Lehmann et al., 2011).
A quantitative Western blotting approach yielded slightly higher
numbers suggesting that a few dozen tetherin dimers are used to
tether a single virion to the plasma membrane (Venkatesh and
Bieniasz, 2013).
Perez-Caballero et al. (2009) showed that an artiﬁcial teth-
erin molecule consisting of the transmembrane domain of the
transferrin receptor, the coiled-coil ectodomain of the dystrophia
myotonica protein kinase (DMPK), and the GPI modiﬁcation sig-
nal from the urokinase plasminogen activator receptor (uPAR)
was able to restrict the release of budding virions. The fact that
this artiﬁcial protein lacks any sequence homology with tetherin
strongly argues against the requirement of any viral or cellular
cofactors for viral restriction. Instead, the overall conﬁguration
with two membrane anchors and a ﬂexible ectodomain seems
to be sufﬁcient to inhibit virion release. As mentioned above,
a naturally occuring prion protein form also consists of an N-
terminal transmembrane domain, a glycosylated ectodoamin and
a C-terminal GPI-anchor. This prion protein variant is expressed
at the cell surface and it would certainly be interesting to test
whether it displays similar antiviral activities. In agreement with
a direct tethering model involving an axial conﬁguration of the
dimer, tetherin mutants lacking either the GPI-anchor or the
transmembrane domain are non-functional (Neil et al., 2008).
Interestingly, several hereditary diseases affect enzymes of the
GPI-anchor biosynthetic pathway. The best described probably
being paroxysmal nocturnal hemoglobinuria (PNH), a syndrome
that is most commonly caused by mutations in phosphatidylinos-
itol glycan A (PIGA). This protein is part of an enzyme complex
that catalyzes the ﬁrst step of the GPI-anchor synthesis, the addi-
tion of N-acetylglucosamine (GlcNAc) to phosphatidylinositol
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(PI). Subsequently, GlcNAcPI is deacetylated by the ER-resident
enzyme phosphatidylinositol glycan anchor biosynthesis, class L
(PIGL). Mutations in PIGL cause the CHIME syndrome that is
characterized by colobomas, heart defects, ichthyosiform der-
matosis, mental retardation, and ear anomalies (Ng et al., 2012).
Although PIGL has been shown to be required for the transport
of tetherin to the cell surface (Perez-Caballero et al., 2009), viral
infections are not a major symptom of PNH or CHIME syndrome
patients.
In agreement with a direct tethering mechanism of the viral
membrane to the plasma membrane of the host cell, it has been
demonstrated that tetherin is able to inhibit the release of a large
number of enveloped viruses. Studies using either virus-like parti-
cles or replication competent viruses revealed that tetherin restricts
budding of members of alpha-, beta-, gamma-, and deltaretro-
viruses, lentiviruses, and spumaviruses (Neil et al., 2008; Jouvenet
et al., 2009; Groom et al., 2010; Gofﬁnet et al., 2010b), arena- and
ﬁloviruses (Jouvenet et al., 2009; Sakuma et al., 2009; Radoshitzky
et al., 2010), as well as paramyxo- and rhabdoviruses (Radoshitzky
et al., 2010; Weidner et al., 2010; Sarojini et al., 2011; Kong et al.,
2012). Interestingly, viruses that bud from intracellular mem-
branes such asHSV-1 orHCoV-229E are also restricted by tetherin
(Blondeau et al., 2013; Wang et al., 2014). The effect of teth-
erin on HCV replication is still controversial (Dafa-Berger et al.,
2012; Ye et al., 2012; Pan et al., 2013; Amet et al., 2014). Notably,
restriction of virion release is not the only antiviral activity of
tetherin. Thus, seemingly discrepant results may be explained
by the fact that some of the studies analyzed several rounds of
viral replication whereas others focused on the release of viral
particles.
INNATE SENSING AND SIGNALING
Tetherin was identiﬁed in an over-expression screening for acti-
vators of NF-κB (Matsuda et al., 2003). This raised the possibility
that tetherin may also act as signaling molecule in addition to its
role as an inhibitor of virion release. Subsequent studies demon-
strated that antibody-mediated crosslinking of surface tetherin
and – most importantly – virion budding induces the activation
of NF-κB (Galão et al., 2012; Tokarev et al., 2013). Thus, tetherin
may indeed act as a PRR inducing an antiviral immune response
upon binding of budding progeny virions. Notably, however,
activation of NF-κB and restriction of virion release are genet-
ically separable functions of tetherin (Tokarev et al., 2013). The
presence of the GPI-anchor, for example, is essential for inhibi-
tion of virion release but dispensable for signaling. Conversely,
disruption of the tetramerization motif speciﬁcally disrupts sig-
naling (Tokarev et al., 2013). It remains to be determined whether
intrinsic tetherin-mediated activation of NF-κB in the absence
of tethered viral particles is just an in vitro artifact due to over-
expression or plays an important role in vivo. In both scenarios
(over-expression and sensing of budding virions), tetherin seems
to recruit TRAF2 and/or TRAF6 as well as the mitogen-activated
kinase TAK1 and TAB, thereby activating the canonical NF-κB
pathway (Figure 2B; Galão et al., 2012; Tokarev et al., 2013). It is
still unclear how exactly these signaling molecules are recruited to
tetherin. Althoughhuman tetherin contains a putativeTRAFbind-
ing site [PxExx(Ar/Ac)] in its N-terminal cytoplasmic domain,
mutational analyses revealed that this motif is most likely dispens-
able for TRAF6 recruitment (Ye et al., 2002; Galão et al., 2012).
In contrast, mutation of the dual tyrosine motif YxYxxϕ abro-
gated the signaling activity of tetherin. Depletion of AP2 and the
analysis of a naturally occurring Y8H variant of tetherin, however,
revealed that endocytosis is not required for efﬁcient NF-κB acti-
vation (Galão et al., 2012; Sauter et al., 2013). The short isoform
of tetherin fails to act as an innate sensor since it lacks the dual
tyrosine motif. As this isoform acts in a dominant-negative man-
ner on NF-κB activation, it is probably only homodimers of the
long isoform that activate NF-κB (Cocka and Bates, 2012). It is
tempting to speculate that the two N-terminal tyrosine residues
in homodimers are phosphorylated upon virion sensing to recruit
the ﬁrst components of the NF-κB signaling cascade. Interestingly,
a rare single nucleotide polymorphism (SNP) changing arginine
at position 19 to histidine also abrogates the signaling activity
of tetherin without affecting surface expression or its ability to
restrict virion release (Sauter et al., 2013). Unfortunately, this SNP
is probably too rare to assess a possible association with disease
progression.
Remarkably, tetherin has also been shown to directly inter-
act with the immunoglobulin-like transcript 7 (ILT7, LILRA4,
CD85g) on pDCs (Cao et al., 2009; Figure 2C). ILT7 forms
a complex with FcεRIγ which contains an immunoreceptor
tyrosine-based activation motif (ITAM) in its cytoplasmic tail and
induces a calcium-dependent signaling cascade that inhibits the
release of type I interferons and other proinﬂammatory cytokines
from pDCs (Cao et al., 2006; Cho et al., 2008). Thus, it has been
suggested that binding of tetherin to ILT7 may induce a negative
feedback signaling to prevent an uncontrolled prolonged inﬂam-
matory response (Cao et al., 2009). A recent study by Tavano
et al. (2013), however, has challenged this hypothesis. Whereas
antibody-mediated crosslinking of ILT7 signiﬁcantly suppressed
IFNα production by pDCs a modulation of IFN production by
tetherin was not observed in their experimental setup (Tavano
et al., 2013). It is tempting to speculate that binding of ILT7 to
tetherin may also activate tetherin-mediated NF-κB signaling.
STRUCTURAL ORGANIZATION OF THE CELL
In addition to its roles in antiviral immunity tetherin has also
been reported to be an organizer of different cellular structures
and organelles. It has early been shown that tetherin enters the
secretory pathway and is thus mainly transported to the apical
membrane of polarized cells (Kupzig et al., 2003). Knockdown
experiments revealed that tetherin is required for the maintenance
of the apical actin network and microvilli in such cells (Rolla-
son et al., 2007). The protein RICH2 binds to the cytoplasmic
dual tyrosine motif of tetherin and to EBP50, thereby linking
it to Ezrin and the apical actin cytoskeleton (Figure 2D; Rolla-
son et al., 2007). Interestingly, the adaptor protein binding site
is masked in this process and RICH2 binding prevents clathrin-
mediated endocytosis of tetherin (Rollason et al., 2007). RICH2 is
a Rho-type GTPase-activating protein that inhibits the activation
of Rac and Rho which is involved in the remodeling of the actin
cytoskeleton. The activation of these Rho-GTPases is increased in
tetherin-depleted cells (Rollason et al., 2007). Thus, tetherin does
not only act as an anchor and stabilizer of the apical actin network
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but also seems to be involved in the regulation of Rho-GTPases.
Interestingly, the Dictyostelium protein ponticulin that also con-
tains an N-terminal transmembrane domain and a C-terminal
GPI-anchor has also been shown to link the plasma membrane to
the cortical actin network (Hitt et al., 1994a,b).
With the GPI-anchor being localized in a lipid raft and the
transmembrane domain just adjacent to it, tetherin may also
serve as a picket fence stabilizing and organizing membrane
microdomains (Figure 2D; Kupzig et al., 2003). This hypothe-
sis is supported by the observation of Billcliff et al. (2013) that the
N-terminal cytoplasmic tail of tetherin serves as a microdomain-
exclusion motif. Thus, tetherin would link membrane rafts to
the underlying actin cytoskeleton, a role that has previously been
ascribed to the tetraspanin CD82 (Figure 2D; Delaguillaumie
et al., 2004).
Another interesting observation comes from the hamster
ortholog of tetherin called Golgi-resident GPI-anchored protein
(GREG). As the name suggests, hamster tetherin is preferentially
localized to the Golgi apparatus rather than the plasma mem-
brane. GREG is characterized by a stretch of unique EQ tandem
repeats serving as a putative Golgi-retention signal that is absent
from all other tetherin orthologs (Figure 1A; Li et al., 2007). Nev-
ertheless, the overall topology of the protein is conserved and
a certain amount of GREG can also be detected at the plasma
membrane (Perez-Caballero et al., 2009). Thus, it is very likely
that hamster tetherin is still able to inhibit the release of bud-
ding virions despite the presence of a putative Golgi-retention
signal. Interestingly, many circular and ring-like structures rather
than the classical Golgi cisternae were observed in GREG-depleted
cells, suggesting an essential role of GREG in the maintenance of
the Golgi complex (Figure 2E; Li et al., 2007). A similar pheno-
type was observed in cells lacking PIGL which is required for the
GPI-anchor synthesis (Li et al., 2007). A model has been proposed
in which opposing membranes within a cisterna are linked by
GREG dimers (Figure 2E). These dimers may either stabilize the
Golgi structure or act as a sensor, surveilling the distance between
opposing membranes. In this context, Swiecki et al. (2011) made
the interesting observation that tetherin ectodomain dimers are
similar to that formed by BAR-domains. BAR-domains have been
shown to bind and stabilize membrane curvatures (Frost et al.,
2009). It is tempting to speculate that the extracellular part of
tetherin may perform similar activities that are involved in the
sensing of budding virions and/or Golgi structure.
SPECIES-SPECIFIC DIFFERENCES
Tetherin orthologs have been described in many mammalian
species (Figure 1A). The only non-mammalian tetherin has been
identiﬁed in the Chinese alligator Alligator sinensis (accession
numbers: XP_006017475, XP_006017476). The sequence homol-
ogy to mammalian tetherins is, however, only very limited and it
remains to be clariﬁedwhether this reptile protein really represents
a tetherin ortholog.
Like most antiviral genes, tetherin is under high selection pres-
sure and residues in all three domains have been shown to be
under positive selection (Gupta et al., 2009a; McNatt et al., 2009;
Lim et al., 2010). Seven very rare non-synonymous SNPs have
been described in human tetherin (Y8H, R19H, N49S, D103N,
E117A, D129E, and V146L), one of which speciﬁcally abrogates
the sensing and signaling activity of tetherin (Sauter et al., 2013).
A unique characteristic of the human ortholog is the deletion of
ﬁve amino acids in the cytoplasmic N-terminal tail (Figure 1A).
Since these ﬁve amino acids are also absent from the genomes
of the Denisova and Neanderthal, it probably emerged at least
800,000 years ago, before the separation of these ancient hominin
species but after the divergence of humans from non-human pri-
mates (Sauter et al., 2011b). The methionine residue at position
13 of human tetherin is conserved in many orthologs, suggest-
ing that a long and a short isoform of tetherin are expressed in
many mammalian species (Figure 1A). Some species, however,
such as cats, guinea-pigs, horses, or elephants encode only the
short isoform or a variant with deletions in the N-terminal part
(Figure 1A). One well-characterized example is the cat ortholog,
which expresses only the short isoform due to a mutation in the
upstream start codon (Celestino et al., 2012). Since this isoform
lacks the dual tyrosine motif that is required for activation of NF-
κB signaling and binding of RICH2, feline tetherin is probably
deﬁcient in these two functions. The short isoform may, however,
restrict virion release more efﬁciently because it is expressed to
higher levels at the cell surface due to the lack of the endocytosis
signal. Furthermore, a short N-terminal cytoplasmic tail may con-
fer a selective advantage because it reduces the number of target
sites for potential cytoplasmic viral antagonists.
Interestingly, most mammalian tetherin orthologs seem not to
be able to sense viral particles although they express the long iso-
form and contain the dual tyrosine motif. Only human tetherin
and (to a lesser extent) chimpanzee tetherin have been shown
to perform this function (Galão et al., 2012). Although most
experiments have been performed in human cells, it has been
suggested that the deletion of the ﬁve amino acid patch in the
cytoplasmic tail of tetherin during human evolution may have led
to an increased signaling capacity (Galão et al., 2012). Tetherin
orthologs from other species may perform additional functions.
Asmentioned above, hamster tetherin contains uniqueEQ tandem
repeats that may determine its preferentially intracellular localiza-
tion and its involvement in themaintenance of theGolgi apparatus
(Figures 1A and 2E; Li et al., 2007). The Gray-handed night mon-
keyAotus (lemurinus) griseimembra encodes a tetherin variant that
is not able to inhibit virion release. This lack of restriction could
be ascribed to a S164T mutation in the extracellular domain of
tetherin (Figure 1A; Wong et al., 2009). To my knowledge, this is
the only naturally occurring tetherin variant that fails to restrict
virion release.
Sheep, goats, and cows encode two tetherin variants implying
a gene duplication event before the divergence of these ruminants
(Arnaud et al., 2010). At least in sheep, both proteins (BST-2A and
BST-2B) are able to inhibit the release of budding virions, although
they may be differentially expressed in various cell types (Arnaud
et al., 2010). Interestingly, BST-2A is characterized by a truncated
N-terminal domain and appears to restrict retroviral release more
efﬁciently than BST-2B (Figure 1A; Arnaud et al., 2010).
Thus, some tetherin functions such asmaintenance of theGolgi
structure or innate sensing may have evolved relatively recently
during evolution and may hence only be found in few species.
In contrast, the inhibition of virion release is conserved among
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Simian immunodeﬁciency viruses are primate lentiviruses that
have been identiﬁed in more than forty different African primate
species. Most of these viruses use their accessory protein Nef
to counteract tetherin in their respective host species (Jia et al.,
2009; Sauter et al., 2009; Zhang et al., 2009; Schmökel et al., 2011).
Like many other viral antagonists, Nef enhances virion release by
decreasing the surface expression levels of tetherin (Figure 3A;
Götz et al., 2012; Serra-Moreno et al., 2013). However, total cellu-
lar tetherin levels remain unaffected suggesting that Nef sequesters
it to intracellular compartments rather than inducing its degrada-
tion. Indeed, it has been shown that Nef induces clathrin, AP2-
and dynamin2-dependent endocytosis of the restriction factor
(Figure 3A). Mutational analyses revealed that residues within
and adjacent to a highly conserved [D/E]xxxLL motif in the C-
loop of Nef are critical for its anti-tetherin activity (Zhang et al.,
2011; Serra-Moreno et al., 2011; Götz et al., 2012). Although
recruitment of AP2 via this motif is required for Nef-mediated
downmodulation of CD4 (Garcia and Miller, 1991; Lindwasser
et al., 2008), these mutations speciﬁcally disrupted the downmod-
ulation of tetherin (Götz et al., 2012; Serra-Moreno et al., 2013).
Thus, residues surrounding the AP2-binding site may be involved
in the direct binding of tetherin rather than AP2 recruitment. In
agreement with this hypothesis, Serra-Moreno et al. (2013) veri-
ﬁed a direct physical interaction between Nef and the N-terminal
cytoplasmic tail of tetherin. Interestingly, the sensitivity of tetherin
towardNef maps to theDIWKKmotif that ismissing in the human
ortholog (Jia et al., 2009; Sauter et al., 2009; Zhang et al., 2009).
Thus, human tetherin is resistant against Nef-mediated counter-
action and may thus represent a hurdle for successful cross-species
transmissions of SIV to humans (Sauter et al., 2009, 2010).
HIV-1 M AND N Vpu
The currentAIDS pandemic is a sinister example for the enormous
plasticity and adaptability of primate lentiviruses. HIV-1 groups
M, N, O, and P are the result of four independent cross-species
transmission events fromapes to humans (Sharp andHahn,2011).
SIVcpz and SIVgor, the direct precursors of HIV-1 use their Nef
proteins to antagonize the tetherin ortholog of their respective host
species. Although human tetherin is resistant to Nef due to a ﬁve
amino acid deletion in its cytoplasmic tail, pandemic HIV-1 group
M strains mastered this species barrier by switching from Nef-
to Vpu-mediated counteraction (Figure 3B; Sauter et al., 2009).
This evolution of Vpu as an effective tetherin antagonist may have
been an important prerequisite for the pandemic spread of HIV-1
group M (Sauter et al., 2010). Several residues in the transmem-
brane domain of Vpu have been shown to directly interact with
the transmembrane domain of tetherin (Kobayashi et al., 2011;
McNatt et al., 2013). As a consequence, Vpu-mediated counter-
action of tetherin is often species-speciﬁc (Gofﬁnet et al., 2009;
Gupta et al., 2009a; McNatt et al., 2009; Rong et al., 2009). Notably,
an AxxxAxxxAxxxW face in the transmembrane domain of HIV-1
group M Vpu is essential for the counteraction of human tetherin
(Vigan and Neil, 2010). It remains, however, unclear whether these
residues directly interact with the transmembrane domain of teth-
erin or rather confer stability to the alpha-helical structure of
the transmembrane domain (Kleiger et al., 2002; Schneider and
Engelman, 2004).
Although an interaction of Vpu with tetherin at the cell sur-
face has been suggested (Iwabu et al., 2009), it is now quite well
established that both proteins interact in the TGN (Dubé et al.,
2009) and that Vpu inhibits the anterograde transport of teth-
erin to the plasma membrane (Dubé et al., 2009; Hauser et al.,
2010; Andrew et al., 2011; Schmidt et al., 2011). Although this
interaction and sequestration to the TGN may be sufﬁcient for
a partial relief of restriction, full counteraction activity depends
on the presence of a di-serine motif (DSGxxS) in the cytoplasmic
part of Vpu that is phosphorylated by casein kinase II (Mangeat
et al., 2009; Gofﬁnet et al., 2010a; Schindler et al., 2010). Thismotif
recruits the SCF E3 ubiquitin ligase complex via the adaptor pro-
tein βTrCP thereby inducing the subsequent ubiquitination of
tetherin. The exact residues in the cytoplasmic tail of tetherin
that become ubiquitinated are still unclear (Tokarev et al., 2011;
Gustin et al., 2012). The absence of putative ubiquitination sites
in the short isoform of tetherin may, however, explain its relative
resistance against Vpu (Cocka and Bates, 2012). Although some
reports propose an ERAD- and proteasome-dependent degrada-
tion of tetherin (Gofﬁnet et al., 2009; Mangeat et al., 2009; Petris
et al., 2014), it seems more likely that tetherin enters the ESCRT-
dependent endolysosomal pathway upon ubiquitination (Douglas
et al., 2009; Iwabu et al., 2009; Mitchell et al., 2009; Janvier et al.,
2011; Agromayor et al., 2012; Gustin et al., 2012; Kueck and Neil,
2012; Rollason et al., 2013). Interestingly, the presence of a βTrCP-
consensus sequence (DSGxxS) is not absolutely required for efﬁ-
cient anti-tetherin activity (Kluge et al., 2013) and some studies
suggest that the di-serine itself rather than βTrCP recruitment is
required for Vpu-mediated counteraction of tetherin (Schmidt
et al., 2011; Tervo et al., 2011). Whereas Tervo et al. (2011) pro-
pose the binding of an as-yet unknown factor to the di-serine
it is also conceivable that the presence of this motif is required
for the structural integrity of the second alpha-helical domain of
Vpu (Coadou et al., 2002, 2003). Notably, this second alpha-helix
contains a putative ExxxLV trafﬁcking motif that is required for
efﬁcient anti-tetherin activity (Kueck and Neil, 2012) and fusion
of this domain to tetherin was sufﬁcient to remove it from the
sites of budding (McNatt et al., 2013). A similar DxxxLV motif
evolved in the Vpu of a recently isolated highly pathogenic HIV-1
group N strain which counteracted human tetherin as efﬁciently
as pandemic HIV-1 group M Vpus (Sauter et al., 2012). In con-
trast, most of the previously characterized HIV-1 N Vpus do not
contain a DxxxLV motif in their cytoplasmic domain and coun-
teract tetherin only inefﬁciently (Sauter et al., 2009, 2012). This
poor anti-tetherin activity of HIV-1 group N viruses could be a
reason for their very limited spread in the human population.
Similarly, Vpu proteins of non-pandemic HIV-1 groups O and P
have not evolved efﬁcient anti-tetherin activity either (Sauter et al.,
2009, 2011a; Yang et al., 2010b; Petit et al., 2011). Thus, only pan-
demic HIV-1 M strains mastered the tetherin hurdle “perfectly”by
switching from Nef to Vpu to antagonize the human ortholog of
this restriction factor.
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FIGURE 3 | Viral antagonists of tetherin. Schematic structure and
mode of action are shown for (A) SIV Nef, (B) HIV-1 Vpu, (C) HIV-2
Env, (D) HHV-8 K5, (E) Ebolavirus Gp. Tetherin is indicated in blue, the
viral antagonists are shown in red. SIV Nef and HIV-2 Env sequester
tetherin to intracellular compartments without affecting total cellular
tetherin levels. In contrast HIV-1 Vpu and HHV-8 K5 induce the
ubiquitination and subsequent degradation of the restriction factor. The
mechanism of Ebola Gp-mediated tetherin antagonism is still unclear.
Interactions between domains of tetherin and its antagonists are
indicated by red arrows.
HIV-2 AND SIV Env
The second human immunodeﬁciency virus HIV-2 is the result of
at least nine independent cross-species transmissions of SIVsmm
infecting sooty mangabeys to humans (Sharp and Hahn, 2011;
Ayouba et al., 2013). These transmission events gave rise to HIV-
2 groups A–I. HIV-2 does not encode a vpu gene and switched
from Nef to its envelope protein (Env) to antagonize human
tetherin (Le Tortorec and Neil, 2009). Similar to Nef-mediated
counteraction of tetherin, Env does not induce the degradation
of this restriction factor but rather sequesters it to intracellu-
lar compartments, probably the TGN (Figure 3C; Le Tortorec
and Neil, 2009; Hauser et al., 2010). The interaction with teth-
erin occurs very likely via the ectodomain of Env (Lopez et al.,
2010) and depends on an endocytic motif in gp41 (Le Tortorec
and Neil, 2009). Notably, most assays were performed with Env
alleles from HIV-2 group A strains and it remains unclear whether
otherHIV-2 groups also evolvedEnv-mediated anti-tetherin activ-
ity and/or whether the ability to antagonize tetherin correlates
with the spread of the respective HIV-2 group in the human
population.
OTHERS
The broad antiviral activity of tetherin is reﬂected by the fact that a
substantial number of enveloped viruses have evolved antagonists
of this restriction factor. Similar to the retroviral proteins men-
tioned above, most antagonists reduce tetherin levels at the sites
of budding to enable efﬁcient release of progeny virions.
The Herpes simplex virus 1 (HSV-1) glycoprotein M (gM), the
Chikungunya virus non-structural protein 1 (Nsp1) and theEnvof
SIVtan and equine infectious anemia virus (EIAV), for instance,
all reduce the surface expression levels of tetherin (Gupta et al.,
2009b; Blondeau et al., 2013; Jones et al., 2013; Yin et al., 2014).
Neuraminidase (N1 and N2) has been suggested to be the tetherin
antagonist of inﬂuenza viruses (Yondola et al., 2011;Mangeat et al.,
2012; Leyva-Grado et al., 2013) and Sendaivirus uses the fusion
(F) and hemagglutinin-neuraminidase proteins (HN) in concert
to induce the degradation of the restriction factor (Bampi et al.,
2013).
In 2006, tetherin was identiﬁed in a screen for factors that
are downmodulated by the RING-CH ubiquitin ligase K5 of the
Kaposi’s sarcoma-associated herpesvirus (KSHV, HHV-8; Bartee
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et al., 2006). It soon became clear that HHV-8 utilizes K5 to ensure
efﬁcient virion release by inducing the degradation of tetherin. K5
ubiquitinates lysine 18 in the cytoplasmic tail of tetherin thereby
targeting it for proteasomal or ESCRT-dependent endo-lysosomal
degradation (Figure 3D; Mansouri et al., 2009; Pardieu et al., 2010;
Agromayor et al., 2012). In agreement with an ongoing coevo-
lution between tetherin and its viral antagonists, K5 efﬁciently
counteracts human tetherin but fails to antagonize the rhesus
macaque and mouse orthologs (Pardieu et al., 2010). Bartee et al.
(2006) made the interesting observation that MARCH-VIII, the
cellular homolog of K5 is also able to induce the degradation of
tetherin.
In contrast to other tetherin antagonists, the Ebolavirus glyco-
protein (Gp) is able to enhance virion release without decreasing
the surface levels of the restriction factor (Figure 3E; Lopez et al.,
2010; Kühl et al., 2011). Interestingly, removal of tetherin from
lipid rafts is not involved either (Lopez et al., 2010) and Ebolavirus
Gp fails to rescue the release of arenaviruses (Radoshitzky et al.,
2010). Although the exact mechanism of Gp-mediated counterac-
tion of tetherin remains unclear, it has been suggested that tetherin
interacts directly with the GP2 subunit (Kühl et al., 2011). A sim-
ilar mechanism has also been proposed for FIV Env. Morrison
et al. (2014) showed that FIV Env incorporation is required to
antagonize feline tetherin but does not involve a reduction of
total or surface tetherin levels. Like Ebola Gp, FIV Env was not
able to rescue the release of non-cognate particles (Celestino et al.,
2012; Morrison et al., 2014). However, another study suggested
that FIV does not encode a direct antagonist but rather overcomes
restriction by direct cell-to-cell spread (Dietrich et al., 2011).
Thus, virusesmay also evolve evasion strategieswithout directly
targeting tetherin. It has for example been suggested that some
viruses do not induce IFN production in vivo or have evolved
means to inhibit the IFN-mediated expressionof tetherin (Limand
Emerman, 2009; Mangeat et al., 2012). Inﬂuenza virus for instance
does not only use its Neuraminidase protein to directly antagonize
tetherin but may also impede the induction of tetherin via the
viral protein NS1 (Mangeat et al., 2012). To evade restriction some
viruses such as HCV may also bud from internal membranes that
contain no or only low levels of tetherin. Similarly, direct cell-
to-cell spread has been suggested to be used by some viruses to
overcome restriction (Jolly et al., 2010; Dietrich et al., 2011; Ilin-
skaya et al., 2013). Furthermore, the antiviral activity of tetherin
is simply saturated if a large number of virions is budding (Yadav
et al., 2012). Some viruses may even exploit tetherin for their own
beneﬁt: HTLV-1 infected cells produce tetherin-containing extra-
cellular viral assemblies that are transferred to neighboring cells
and are required for efﬁcient spread of infection (Pais-Correia
et al., 2010). Tetherin has also been suggested to enhance the entry
of human cytomegaloviruses and to be required for efﬁcient FIV
particle release (Viswanathan et al., 2011; Morrison et al., 2014).
In summary, viruses have evolved a multiplicity of mechanisms
to counteract, evade or even hijack the restriction imposed by
tetherin.
SUMMARY AND CONCLUDING REMARKS
The continuous arms race between viruses and their hosts has cer-
tainly driven the evolution of the host restriction factor tetherin.
Whereas the ability of tetherin to restrict virion release seems to
be an ancient function that is highly conserved among all mam-
malian orthologs, some species have evolved unique features of
this protein. Bovids, for instance, express two tetherin homologs
that probably differ in their expression pattern and may thus facil-
itate adaptation to emerging viral infections (Arnaud et al., 2010).
Human and (to a lesser extent) chimpanzee tetherin are apparently
the only tetherin orthologs that act as innate sensors activating the
NF-κB signaling cascade upon binding of viral particles (Galão
et al., 2012). Conversely, tetherin also exerted a substantial selec-
tion pressure on viral evolution. Diverse enveloped viruses have
evolved effective ways of escaping restriction. Whereas some viral
proteins directly target tetherin and sequester it away from the
sites of budding and/or induce its degradation, other viruses may
overcome restriction via cell-to-cell spread or prevent the mount-
ing of an IFN response to inhibit expression of tetherin and other
ISGs.
The AIDS pandemic is an impressive example of this ongoing
coevolution between viruses and tetherin. Analyses of different
HIV-1 groups revealed that counteraction of tetherin may be a
prerequisite for the efﬁcient spread of lentiviruses in the human
population (Sauter et al., 2010): in contrast to pandemic HIV-
1 group M viruses, non-pandemic HIV-1 groups N, O, and P
strains failed to evolve efﬁcient tetherin antagonists after cross-
species transmissions of SIV to humans (Sauter et al., 2009,2011a).
Notably, however, patients infected with non-pandemic HIV-1
strains develop high viral loads and ultimately progress to AIDS
although tetherin is not efﬁciently counteracted (Ayouba et al.,
2000; Plantier et al., 2009; Vessière et al., 2010; Delaugerre et al.,
2011). This strongly suggested that the evolution of a speciﬁc teth-
erin antagonist is required for efﬁcient viral transmission and
spread of the virus in the population rather than for efﬁcient
replication within an infected individual. In agreement with this,
the presence of Vpu did not or only slightly enhance the cyto-
pathicity of HIV-1 in humanized mouse models (Aldrovandi and
Zack, 1996; Sato et al., 2012). Furthermore, Vpu boosted the ini-
tial phase of R5- and X4-tropic HIV-1 replication but was less
important for viral dissemination during late stages of infec-
tion (Aldrovandi and Zack, 1996; Sato et al., 2012; Dave et al.,
2013). These observations would be in agreement with a model in
which cell-free virions are involved in transmission of the virus,
whereas spread within patients occurs mainly via direct cell-to-
cell spread that overcomes tetherin restriction (Jolly et al., 2010;
Sato et al., 2012).
A recent publication by Pickering et al. (2014), however, chal-
lenged this hypothesis revealing that potent anti-tetherin activity
is not only a characteristic of transmitted/founder viruses but
preserved throughout infection. Thus, efﬁcient counteraction of
tetherin may confer a selective advantage during all stages of viral
infection. One possible explanation for this observation is that
tetherinmay still restrict direct cell-to-cell spreadof HIV-1. In con-
trast to Jolly et al. (2010), Kuhl et al. (2010) reported that tetherin
reduces the transfer of infectious material via virological synapses.
Similarly, Casartelli et al. (2010) also showed that tetherin is
able to restrict direct cell-to-cell spread. They suggest that teth-
erin induces the transfer of large patches of cross-linked viruses
with reduced infectivity from producer to target cells (Casartelli
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et al., 2010). Alternatively, the contribution of cell-free virions to
persistant HIV-1 infection may be higher than initially thought.
This hypothesis is supported by the successful use of broadly neu-
tralizing antibodies in recent vaccine trials (Klein et al., 2013).
Furthermore, different functions of tetherin may exert selection
pressure at different stages of the viral replication cycle. Thus,
even if restriction of virion release primarily affects transmission
efﬁciency and early viral dissemination, the sensing activity of teth-
erin (Galão et al., 2012) may still exert a high selection pressure on
Vpu function during late stages of infection. In addition to its
restriction and signaling functions, tetherin seems to enhance the
antibody opsonization of infected cells by increasing the accessibil-
ity of epitopes on the cell surface (Alvarez et al., 2014; Pham et al.,
2014). As a result, Vpu-mediated down-modulation of tetherin
may confer a selective advantage throughout all stages of infection
because it reduces the susceptibility of infected cells to NK-cell-
mediated antibody-dependent cellular cytotoxicity (Alvarez et al.,
2014; Pham et al., 2014).
Several additional mouse studies afﬁrmed a crucial role of
tetherin in restricting viral infection in vivo. In contrast to
the humanized mouse models described above, these stud-
ies focused on the infection of immunocompetent mice with
murine pathogens. In a study by Liberatore and Bieniasz (2011),
viral loads were signiﬁcantly increased in tetherin knockout
mice infected with Moloney MLV and these mice progressed to
disease faster than their wild type littermates. Increased repli-
cation of Moloney MLV in tetherin-deﬁcient mice was also
conﬁrmed by a study of Swiecki et al. (2012). Paradoxically,
however, viral titers in the lungs were reduced upon infection
with vesicular stomatitis virus in this mouse model (Swiecki
et al., 2012). A third in vivo study took advantage of a poly-
morphism that disrupts the ﬁrst start codon of tetherin (Barrett
et al., 2012). As a consequence, these mice express only the
short form of tetherin which lacks the tyrosine-based endo-
cytosis signal and is therefore expressed to higher levels at
the cell surface. In agreement with the other two studies, the
increased tetherin expression resulted in decreased viral loads
and reduced the pathogenic effects of Friend MLV (Barrett et al.,
2012).
The observation that tetherin knockout mice do not show
any obvious developmental or functional defects (Liberatore and
Bieniasz, 2011) argues against essential cellular roles of tetherin
beyond antiviral immunity. Some activities of tetherin such as
the ability to induce the NF-κB signaling cascade may, however,
be unique for the human ortholog. Thus, mouse models cannot
fully recapitulate all characteristics of human tetherin and further
studies are warranted to characterize the relative contribution of
different tetherin functions in antiviral activity and beyond.
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